Are Investors Undervaluing argenx SE (EBR:ARGX) By 34%?
Dec 21
Have your own idea? Try our Stock Screener
Belgian (BEL20) Biotech Industry Analysis
UpdatedDec 26, 2024
DataAggregated Company Financials
Companies3
- 7D-0.9%
- 3M26.9%
- 1Y74.7%
- YTD75.1%
Over the last 7 days, the Biotech industry has dropped 1.7%, driven by argenx declining 1.7%. Meanwhile, European Medical Solutions actually outperformed within the industry, gaining 14% in the last week. This takes the industry's 12 month performance to a gain of 37%. Earnings are forecast to grow by 55% annually.
Industry Valuation and Performance
Has the Belgian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 26 Dec 2024 | €36.6b | €1.9b | -€47,521,397.20 | n/a | -769.2x | 19.5x |
| Sat, 23 Nov 2024 | €35.2b | €1.9b | -€47,585,866.00 | n/a | -740.3x | 18.7x |
| Mon, 21 Oct 2024 | €30.5b | €1.6b | -€196,923,572.50 | n/a | -154.9x | 19.4x |
| Wed, 18 Sep 2024 | €28.9b | €1.5b | -€192,310,196.50 | n/a | -150x | 18.8x |
| Fri, 16 Aug 2024 | €28.7b | €1.6b | -€195,356,164.00 | n/a | -146.9x | 18.5x |
| Sun, 14 Jul 2024 | €25.7b | €1.4b | -€309,697,565.10 | n/a | -82.9x | 18.7x |
| Tue, 11 Jun 2024 | €21.1b | €1.4b | -€313,696,468.90 | n/a | -67.3x | 15.2x |
| Thu, 09 May 2024 | €21.9b | €1.2b | -€283,931,827.10 | n/a | -77.1x | 17.9x |
| Sat, 06 Apr 2024 | €21.3b | €1.2b | -€281,600,908.40 | n/a | -75.5x | 17.6x |
| Mon, 04 Mar 2024 | €21.3b | €1.2b | -€303,771,908.40 | n/a | -70.2x | 17.6x |
| Wed, 31 Jan 2024 | €20.8b | €1.0b | -€288,808,944.00 | n/a | -72.1x | 19.9x |
| Fri, 29 Dec 2023 | €20.6b | €1.0b | -€284,330,051.00 | n/a | -72.6x | 20.1x |
| Sun, 26 Nov 2023 | €26.8b | €1.0b | -€286,707,116.00 | n/a | -93.6x | 25.9x |
| Tue, 24 Oct 2023 | €26.8b | €875.0m | -€448,979,302.00 | n/a | -59.6x | 30.6x |
| Thu, 21 Sep 2023 | €28.7b | €868.3m | -€451,586,994.00 | n/a | -63.5x | 33x |
| Sat, 19 Aug 2023 | €26.4b | €847.1m | -€455,120,411.00 | n/a | -58x | 31.2x |
| Mon, 17 Jul 2023 | €18.7b | €647.2m | -€544,146,437.00 | n/a | -34.4x | 28.9x |
| Wed, 14 Jun 2023 | €20.5b | €671.8m | -€564,205,994.00 | n/a | -36.4x | 30.5x |
| Fri, 12 May 2023 | €20.7b | €638.7m | -€549,679,400.00 | n/a | -37.6x | 32.4x |
| Sun, 09 Apr 2023 | €19.7b | €457.3m | -€731,958,683.00 | n/a | -26.9x | 43x |
| Tue, 07 Mar 2023 | €18.0b | €314.5m | -€913,033,782.00 | n/a | -19.7x | 57.3x |
| Thu, 02 Feb 2023 | €19.3b | €308.3m | -€894,443,495.00 | n/a | -21.6x | 62.7x |
| Sat, 31 Dec 2022 | €19.7b | €314.0m | -€906,950,370.00 | n/a | -21.7x | 62.7x |
| Mon, 28 Nov 2022 | €20.5b | €322.8m | -€933,182,311.00 | n/a | -22x | 63.6x |
| Wed, 26 Oct 2022 | €21.9b | €190.2m | -€969,254,938.00 | n/a | -22.6x | 115x |
| Fri, 23 Sep 2022 | €20.1b | €174.0m | -€984,394,855.00 | n/a | -20.4x | 115.6x |
| Sun, 21 Aug 2022 | €21.1b | €168.9m | -€960,417,172.00 | n/a | -22x | 125.1x |
| Tue, 19 Jul 2022 | €19.9b | €400.8m | -€645,857,028.00 | n/a | -30.9x | 49.7x |
| Thu, 16 Jun 2022 | €17.9b | €388.8m | -€627,261,621.00 | n/a | -28.6x | 46.1x |
| Sat, 14 May 2022 | €16.4b | €388.6m | -€626,885,955.00 | n/a | -26.2x | 42.3x |
| Mon, 11 Apr 2022 | €16.8b | €506.1m | -€428,535,280.00 | n/a | -39.3x | 33.2x |
| Wed, 09 Mar 2022 | €12.7b | €515.8m | -€418,959,286.00 | n/a | -30.2x | 24.6x |
| Fri, 04 Feb 2022 | €12.5b | €464.2m | -€398,731,190.00 | n/a | -31.3x | 26.9x |
| Sun, 02 Jan 2022 | €16.5b | €466.6m | -€400,615,185.00 | n/a | -41.3x | 35.4x |
Price to Earnings Ratio
-41.3x
Current Industry PE
- There are only 3 companies in the Belgian Biotechs industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 58% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Belgian Healthcare industry?
| BE Market | -0.21% | |
| Healthcare | 0.82% | |
| Biotech | -0.88% | |
| Biotech | -0.88% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| CYAD Celyad Oncology | €0.73 | 2.7% +€787.1k | 92.1% | PS420x |
